Inventor · disambiguated record
Angela Norton
Also filed as: NORTON ANGELA · NORTON ANGELA W · NORTON ANGELA WYNNE
12 granted patents·23 pending applications·23 citations·filing 2011–2025
87Inventor score
Files withSHIRE HUMAN GENETIC THERAPIES16TAKEDA PHARMACEUTICALS CO6DYNAMICURE BIOTECHNOLOGY LLC5SHIRE NPS PHARMACEUTICALS INC3FLAGSHIP PIONEERING INNOVATIONS VII LLC2
Top patents by PatentIndex Score
35 records- 0189US9814764B2Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Nov 14, 2017·9 cites·20 claims
- 0286US10722559B2Mannose-6-phosphate bearing peptides fused to lysosomal enzymesSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Jul 28, 2020·5 cites·11 claims
- 0383US11660328B2GLP-2 analogs and peptibodies for administration before, during or after surgeryTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted May 30, 2023·2 cites·8 claims
- 0483US11065307B2Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moietySHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Jul 20, 2021·2 cites·8 claims
- 0580US10603364B2Lysosomal targeting and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Mar 31, 2020·2 cites·7 claims
- 0679US12291556B2Parathyroid hormone variantsTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted May 6, 2025·0 cites·17 claims
- 0778US11634468B2Parathyroid hormone variantsSHIRE NPS PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·5 claims
- 0869US8775146B2Crystal structure of human alpha-N-acetylglucosaminidaseMEIYAPPAN MUTHURAMAN·Filed 2011·Granted Jul 8, 2014·2 cites·5 claims
- 0969US2025170227A1Conjugated c1 esterase inhibitor and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 1069US2025257112A1Parathyroid hormone variantsTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 1167US2023031280A1Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditionsSHIRE NPS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1263US2024034779A1Antibodies targeting complement factor d and uses therofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1361US9708590B2Crystal structure of human α-N-acetylglucosaminidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Jul 18, 2017·0 cites·20 claims
- 1456US2020376095A1Mannose-6-phosphate bearing peptides fused to lysosomal enzymesSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 1555US10729746B2Recombinant placenta growth factor for treating Duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Aug 4, 2020·0 cites·15 claims
- 1654US2025375499A1Immunoreceptor inhibitory proteins and related methodsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2025·Application pending·0 cites
- 1754US2018333473A1Conjugated C1 Esterase Inhibitor and Uses ThereofSHIRE HUMAN GENETIC THERAPIES·Filed 2018·Application pending·0 cites
- 1853US2024150466A1Anti-igfbp7 constructs and uses thereofDYNAMICURE BIOTECHNOLOGY LLC·Filed 2022·Application pending·0 cites
- 1953US2024141048A1Anti-vista constructs and uses thereofDYNAMICURE BIOTECHNOLOGY LLC·Filed 2022·Application pending·0 cites
- 2052US2022133863A1Treatment of sanfilippo syndrome type bSHIRE HUMAN GENETIC THERAPIES·Filed 2021·Application pending·0 cites
- 2152US2020199192A1Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditionsSUN KEFENG·Filed 2018·Application pending·0 cites
- 2252US2025353881A1Immunoreceptor inhibitory proteins and related methodsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2025·Application pending·0 cites
- 2351US2017360905A1Conjugated C1 Esterase Inhibitor and Uses ThereofSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 2451US2023365705A1Anti-cd93 constructs and uses thereofDYNAMICURE BIOTECHNOLOGY LLC·Filed 2021·Application pending·0 cites
- 2550US2023322935A1Anti-cd93 constructs and uses thereofDYNAMICURE BIOTECHNOLOGY LLC·Filed 2021·Application pending·0 cites
- 2649US2023235075A1Anti-cd93 constructs and uses thereofDYNAMICURE BIOTECHNOLOGY LLC·Filed 2021·Application pending·0 cites
- 2745US2021355187A1Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditionsSHIRE NPS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2844US12209116B2Recombinant human C1 esterase inhibitor and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jan 28, 2025·0 cites·9 claims
- 2942US9597376B2Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitisSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Mar 21, 2017·0 cites·14 claims
- 3041US2020247856A1Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 3139US2018362604A1Recombinant Follistatin-FC Fusion Proteins and Use in Treating Duchenne Muscular DystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2018·Application pending·0 cites
- 3239US2017202929A1Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitisSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 3337US2017267986A1Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Application pending·0 cites
- 3435US2011318327A1Treatment of sanfilippo syndrome type bCONCINO MICHAEL F·Filed 2011·Application pending·0 cites
- 3534US2016130324A1C1 Inhibitor Fusion Proteins and Uses ThereofSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Angela Norton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →